COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05JAC
|
|||
| Drug Name |
Linagliptin
|
|||
| Synonyms |
Linagliptin; BI 1356; Ondero; 668270-12-0; Tradjenta; BI-1356; Linagliptin (BI-1356); UNII-3X29ZEJ4R2; BI-1356-BS; CHEMBL237500; 3X29ZEJ4R2; CHEBI:68610; C25H28N8O2; Linagliptin
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) | Phase 3 | [1] | |
| Other Indication | Type 2 diabetes | Approved | [2] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H28N8O2
|
|||
| Canonical SMILES |
CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
|
|||
| InChI |
1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
|
|||
| InChIKey |
LTXREWYXXSTFRX-QGZVFWFLSA-N
|
|||
| CAS Number |
CAS 668270-12-0
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:68610
|
|||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN dipeptidyl peptidase 4 (DPP-4) | Target Info | Inhibitor | [3], [4] |
| Linagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor. Evidence suggests that DPP4i modulate inflammation and exert anti-fibrotic activity. These properties are of potential use for halting progression to the hyperinflammatory state associated with severe COVID-19. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | ClinicalTrials.gov (NCT04371978) Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19. U.S. National Institutes of Health. | |||
| 2 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 208026 | |||
| 3 | DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19 Diabetes Metab Res Rev. 2020 Apr 26. | |||
| 4 | Effects of Dipeptidyl Peptidase 4 Inhibition on Inflammation in Atherosclerosis: A 18 F-fluorodeoxyglucose Study of a Mouse Model of Atherosclerosis and Type 2 DiabetesAtherosclerosis. 2020 Apr 10. pii: S0021-9150(20)30194-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.